Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 5

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 8
Chunk 5
---
946,988$10 $1,098 $(25,277)$— $(24,169)Issuance of Series B convertible preferred stock, net of issuance costs—— —— 28,019,18182,976 —— —— — — — — Unrealized gain on marketable securities—— —— —— —— —— — — 6 6 Vesting of early exercised stock options—— —— —— —— 22,372— 76 — — 76 Share-based compensation—— —— —— —— —— 1,343 — — 1,343 Net loss—— —— —— —— —— — (69,968)— (69,968)Balance as of December 31, 202321,977,282$44,621 2,950,548$9,893 28,019,181$82,976 2,744,184$5,900 1,969,360$10 $2,517 $(95,245)$6 $(92,712)

See accompanying notes to consolidated financial statements.

(1)Retroactively recast for the reverse recapitalization as described in Note 3.

104

Table of Contents

LENZ THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands)

Year Ended December 31,20242023Cash flows from operating activitiesNet loss$(49,769)$(69,968)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization58 15 Loss on disposal of property and equipment16 — Accretion of discounts on marketable securities(4,017)(1,057)Change in fair value of preferred stock warrants1,047 (123)Share-based compensation expense6,365 1,343 Changes in operating assets and liabilities:Prepaid expenses and other current assets25 761 Accounts payable(4,279)856 Accrued liabilities(7,460)7,783 Other assets(1,377)10 Net cash used in operating activities(59,391)(60,380)Cash flows from investing activitiesPurchases of marketable securities(241,911)(52,091)Proceeds from maturities of marketable securities87,900 22,500 Purchases of property